Immatics (IMTX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.00%. A quarter ago, it was expected that this company would post a loss of $0.38 per share when it actually produced a loss of $0.66, delivering a surprise of -73.68%.Over the last four quarters, the company has surpassed con ...

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion continues to show strong clinical benefit and favorable tolerability in 16 patients with metastatic uveal melanoma in latest update on Phase 1b data presented at the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11.0 months, mPFS of 8 ...

Immatics (NasdaqCM:IMTX) Update / Briefing November 12, 2025 08:30 AM ET Company ParticipantsGraig Suvannavejh - Managing DirectorCarsten Reinhardt - Chief Development OfficerJames Shin - Director of Biopharma Equity ResearchJonathan Chang - Senior Managing DirectorHarpreet Singh - CEOConference Call ParticipantsPaul Jeng - Research AnalystEric Schmidt - Biotechnology AnalystClara Dong - VP and Equity Research Analyst in BiotechnologyNone - AnalystSebastiaan van der Schoot - Equity Research Analyst of Life ...

Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily pre-treated, last-line patients with a range of solid tumors IMA402 PRAME Bispecific at RP2D range resulted in a 30% cORR (6/20) across all indications, including 29% (4/14) in melanoma and 2/3 confirmed responses in ovarian carcinoma IMA401 MAGEA4/8 Bispecific at ≥1 mg resulted in a 25% cORR (2/8) ...

Core Insights - Immatics N.V. has appointed Amie Krause as Chief People Officer effective October 27, 2025, to lead human resources and organizational development as the company transitions to a commercial stage [1][2] - The company aims to strengthen its global leadership in precision targeting of PRAME, a target expressed in over 50 cancers, through enhanced organizational excellence and efficiency [2][3] Company Overview - Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, with a robust clinical pipeline that includes TCR T-cell therapies and TCR bispecifics [3] - The company is committed to making a meaningful impact on the lives of cancer patients by advancing its PRAME product candidates, including the lead candidate anzu-cel [3] Leadership and Experience - Amie Krause brings over 20 years of experience in organizational growth and talent alignment, having previously held senior HR roles at Dompé, Revance Therapeutics, Atara Biotherapeutics, and Amgen [2] - Krause's background includes leading global commercial operations and serving as an adjunct professor, indicating a strong blend of industry and academic experience [2]

Core Insights - Immatics N.V. announced updated data from a Phase 1b trial of anzu-cel PRAME cell therapy for patients with metastatic uveal melanoma, highlighting its potential to improve treatment outcomes in this challenging patient population [1][3][4] Patient Population - The trial involved 16 patients with metastatic uveal melanoma, who received a one-time infusion of anzu-cel at a recommended Phase 2 dose of 1 to 10 billion total TCR T cells, with a median infused dose of approximately 4 billion TCR T cells [4][5] - Patients had a median of 2 lines of prior systemic treatments and a median target lesion sum diameter of 103 mm, with 81% having liver and extrahepatic metastasis [4] Anti-tumor Activity and Durability - The updated data showed a confirmed objective response rate (cORR) of 67% (10 out of 15 patients) and a disease control rate (DCR) of 88% (14 out of 16 patients) [6] - The median duration of response (mDOR) was 11 months, with a median progression-free survival (mPFS) of 8.5 months, and median overall survival (mOS) not reached at 14.3 months of follow-up [6][5] - Anti-tumor activity was observed across various metastases, including liver lesions, with a median shrinkage of 49.6% in liver target lesions [7][5] Safety Profile - Anzu-cel demonstrated a favorable tolerability profile, consistent with its overall safety profile, with the most frequent treatment-emergent adverse events being cytopenias associated with lymphodepletion [9][12] - Cytokine release syndrome (CRS) was mostly Grade 1 or 2, with no long-term CRS observed, and most cases resolved by day 14 [12][9] Development Path - Based on the promising clinical data, Immatics has initiated a Phase 2 cohort with approximately 30 patients planned, conducted at select centers in the U.S. and Germany [14] - Prospective PRAME testing is no longer required for inclusion in the clinical trial due to the high prevalence of PRAME expression in uveal melanoma [14] Company Overview - Immatics is a clinical-stage biopharmaceutical company focused on precision targeting of PRAME, with a broad pipeline that includes multiple product candidates and therapeutic modalities [16][18] - Anzu-cel is part of a larger strategy to develop therapies for various cancers expressing PRAME, with ongoing trials in both uveal and cutaneous melanoma [17][15]

Core Insights - Immatics N.V. is developing a cell therapy named Anzu-cel (anzutresgene autoleucel, IMA203) targeting melanoma and other potential cancers, which could generate hundreds of millions or more in annual revenue [1] Company Overview - The company has already produced some data regarding Anzu-cel, indicating progress in its development [1] Market Focus - The focus is on trading around significant events such as trial results and NDA/BLA approvals, particularly in the biotech sector regulated by the FDA [1]

Core Insights - Immatics N.V. is developing a cell therapy named Anzu-cel (anzutresgene autoleucel, IMA203) targeting melanoma and other potential cancers, which has the potential to generate hundreds of millions or more in annual revenue [1] Company Overview - The company has already produced some data regarding Anzu-cel, indicating progress in its development [1] Market Potential - The anticipated revenue from Anzu-cel suggests a significant market opportunity within the oncology sector [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - Immatics N.V. has appointed Venkat Ramanan, Ph.D., as Chief Financial Officer, effective immediately, bringing over 25 years of experience in the biopharmaceutical industry [1][2] - Dr. Ramanan's expertise includes facilitating product launches, establishing scalable operations, and enabling corporate transactions, which will support Immatics' growth and commercialization efforts [1][2] - The company is focused on advancing its PRAME cell therapy, anzu-cel, towards commercialization for patients with metastatic melanoma [2][3] Company Overview - Immatics is a clinical-stage biopharmaceutical company and a global leader in precision targeting of PRAME, a target expressed in over 50 cancers [3] - The company has a robust clinical pipeline with the broadest PRAME franchise, including TCR T-cell therapies and TCR bispecifics [3]